Treatment and prevention of respiratory syncytial virus lower respiratory tract infection: Long-term effects on respiratory outcomes

American Journal of Respiratory and Critical Care Medicine

Volumn 163, Issue 3 II, 2001, Pages

  Simoes, Eric A F ^a,b  

^a Children's Hospital Colorado   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BUDESONIDE; CROMOGLYCATE DISODIUM; PREDNISOLONE; RIBAVIRIN; STEROID;

ACUTE PHASE RESPONSE; BRONCHIOLITIS; CONFERENCE PAPER; DISEASE PREDISPOSITION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SENSITIZATION; TREATMENT OUTCOME; VIRUS REPLICATION; WHEEZING;

EID: 0035063863     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.163.supplement_1.2011112     Document Type: Conference Paper

References (30)

1. Wheezing, asthma, and pulmonary function 10 years after infection with respiratory syncytial virus in infancy
2. Respiratory status and allergy after bronchiolitis
3. Respiratory status and allergy nine to 10 years after acute bronchiolitis
4. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7
5. Association of radiologically ascertained pneumonia before age 3 yr with asthmalike symptoms and pulmonary function during childhood: A prospective study
6. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years
7. Long-term prospective study in children after respiratory syncytial virus infection
8. Respiratory illness after severe respiratory syncytial virus disease in infancy in The Gambia
9. Pathogenesis and treatment of bronchiolitis
10. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: Potential effect of ribavirin on long term pulmonary function
11. Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo
12. Prospective follow-up and pulmonary functions from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis
13. Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report
14. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract
15. Potential mechanisms causing delayed effects of RSV infection
16. RSV and asthma: The role of monocytes
17. Neural mechanisms and mechanisms of prevention of RSV sequelae: Animal studies
18. The functional response of infants with persistent wheezing to nebulized beclomethasone dipropionate
19. Nebulised beclomethasone dipropionate in recurrent obstructive episodes after acute bronchiolitis
20. Anti-inflammatory therapy reduces wheezing after bronchiolitis
21. Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing
22. Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing
23. Long-term effects of prednisolone in the acute phase of bronchiolitis caused by respiratory syncytial virus
24. Inhaled corticosteroids during and after respiratory syncytial virus-bronchiolitis may decrease subsequent asthma
25. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis
26. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children
27. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis
28. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
29. Asthma related clinical and physiologic outcomes in high risk children 5-9 years after prophylaxis with RSV-IgIV
30. Childhood sequelae of infant lung disease: Exercise and pulmonary function abnormalities after bronchopulmonary dysplasia